


What is claimed is:

1. A compound according to Formula (1):



- 5 wherein:

X is selected from the group consisting of CH_2 , NR_2 , O , NR_2CO , CONR_2 and a bond;

Y represents O , CH_2 or a bond:

Z represents H or F ;

- 10 R is selected from the group consisting of:

C_{2-6} alkyl optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl; C_{2-6} alkenyl optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl; C_{2-6} alkynyl optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl; $(\text{CH}_2)_n\text{—C}_{3-6}$ carbocycle optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl; $(\text{CH}_2)_n\text{—R}_3$ {where R_3 is phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane or benzo[1,3]dioxole; R_3 is optionally substituted by one or more Cl , Br , I , C_{1-3} alkyl optionally substituted by one to three F , or C_{1-2} alkoxy, optionally substituted by one to three F };

- 20 R_1 is selected from the group consisting of:

hydrogen, C_{1-3} substituted alkyl, C_{2-3} substituted alkenyl, C_{2-3} substituted alkynyl, $(\text{CH}_2)_n\text{—C}_{3-6}$ substituted carbocycle, aryl, heteroaryl, heterocyclic, and aminocarbonyl provided that X is $(\text{CH}_2)_n$ when R_1 represents aminocarbonyl;

R_2 represents:


- 25 hydrogen, or C_{1-3} substituted alkyl;

X represents $(\text{CH}_2)_n$, NR_2 , O , NR_2CO , CONR_2 or a bond;

Y represents O , CH_2 or a covalent bond;

Z represents hydrogen or fluorine; preferably fluoroine; and n represents an interger between 0 and 2 or a salt, solvate, or physiologically functional derivative thereof.

2. A compound as claimed in claim 1, with the following absolute configuration:



5

wherein:

X is selected from the group consisting of CH_2 , NR_2 , O , NR_2CO , CONR_2 and a bond;

Y represents O , CH_2 or a bond:

10 Z represents H or F;

3. A compound as claimed in claim 1, wherein $\text{X} = \text{CH}_2$ or a bond; or a salt, solvate, or physiologically functional derivative thereof.

15 4. A compound as claimed in claim 1, wherein $\text{X} = \text{NR}_2$; or a salt, solvate, or physiologically functional derivative thereof.

5. A compound according to claim 3 selected from the group consisting of:

N-[(R)-2-(5-Benzo[1,3]dioxol-5-yl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxyformamide;

20 N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxyformamide;

N-Hydroxy-N-{(R)-2-[5-(7-methoxy-benzofuran-2-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-{(R)-2-[5-(1,2,3,4-tetrahydroquinolin-6-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

25 N-Hydroxy-N-{(R)-2-[5-(1,2,3,4-tetrahydro-quinolin-8-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-[(R)-2-(5-pyridin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;

N-{(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-

- formamide;
N-[(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-hydroxy-
formamide;
N-[(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-hydroxy-
5 formamide;
N-Hydroxy-N-[(R)-2-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-
formamide;
N-Hydroxy-N-[(R)-2-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-
formamide;
10 N-[(R)-2-[5-(2,3-Dichloro-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-
hydroxy formamide;
N-Hydroxy-N-[(R)-2-[5-(4-methoxy-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-
formamide;
N-[(R)-2-[5-[4-(4-Acetyl-piperazin-1-yl)-phenoxy-methyl]-[1,3,4]oxadiazol-2-yl]-
15 heptyl]-N-hydroxy-formamide;
N-Hydroxy-N-[(R)-2-[5-(1-methyl-1H-pyrrol-2-ylmethyl)-[1,3,4]oxadiazol-2-yl]-
heptyl]-formamide;
N-Hydroxy-N-[(R)-2-[5-(5-pyridin-2-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-
formamide;
20 N-Hydroxy-N-[(R)-2-[5-(5-pyridin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-
formamide;
N-Hydroxy-N-[(R)-2-[5-(2,6-dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-
formamide;
N-Hydroxy-N-[(R)-2-[5-(1H-indol-3-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-
25 formamide;
N-[(R)-2-[(S)-5-(2,3-Dihydro-benzo[1,4]dioxin-2-yl)-[1,3,4]oxadiazol-2-yl]-
heptyl]-N-hydroxy-formamide;
N-[(R)-2-[5-(5-Benzofuran-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxy-
formamide;
30 N-Hydroxy-N-[(R)-2-[5-(5-pyrimidin-2-yl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
N-[(R)-2-[5-(2,3-Dihydro-benzo[d]isoxazol-3-ylmethyl)-[1,3,4]oxadiazol-2-yl]-

- heptyl}-N-hydroxy-formamide;
N-Hydroxy-N-[(R)-2-(5-phenoxy-methyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
N-Hydroxy-N-[(R)-2-[(S)-5-(1,2,3,4-tetrahydro-isoquinolin-3-yl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;
- 5 N-Hydroxy-N-[(R)-2-[5-(4-imidazol-1-yl-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;
N-Hydroxy-N-[(R)-2-[5-(quinolin-6-yloxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;
5-{(R)-1-[(Formyl-hydroxy-amino)-methyl]-hexyl}-[1,3,4]oxadiazole-2-carboxylic acid phenylamide;
- 10 N-Hydroxy-N-[(R)-2-(5-phenylaminomethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
N-[(R)-2-[5-(2-Chloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-Hydroxy-formamide;
- 15 N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-3-cyclohexyl-propyl]-N-hydroxyformamide.
N-[(R)-2-[5-[2-(1H-Benzoimidazol-2-yl)-ethyl]-[1,3,4]oxadiazol-2-yl]-heptyl]-N-Hydroxy-formamide;
N-Hydroxy-N-[(R)-2-[5-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;
- 20 N-Hydroxy-N-[(R)-2-[5-(3-methyl-isoxazol-5-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;
N-Hydroxy-N-[(R)-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;
N-Hydroxy-N-2-[5-[4-(trifluoromethyl-pyrimidin-2-ylamino)-methyl]-[1,3,4]oxadiazol-2-yl]-heptyl)-formamide;
- 25 [1,3,4]oxadiazol-2-yl]-heptyl)-formamide;
N-[(R)-2-[5-(1H-Benzoimidazol-2-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-hydroxy-formamide;
N-Hydroxy-N-[(R)-2-(5-morpholin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
- 30 N-Hydroxy-N-[(R)-2-[5-[3-(trifluoromethyl-phenylamino)-methyl]-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;

N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-3-cyclopentyl-propyl]-N-hydroxyformamide;
 N-Hydroxy-N-[(R)-2-(5-methyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide; and
 N-Hydroxy-N-((R)-2-{5-[2-(1H-indol-3-yl)-ethyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-
 formamide.

5

6. A compound according to claim 5 selected from the group consisting of:

N-Hydroxy--[(R)-2-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;

N-(5-{(R)-1-[(Formyl-hydroxy-amino)-methyl]-hexyl}-[1,3,4]oxadiazol-2-yl)-

10

benzamide;

N-{(R)-2-[5-(Chloro-trifluoromethyl-phenylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-
 hydroxy-formamide;

N-Hydroxy-N-{(R)-2-[5-(methyl-phenyl-amino)-[1,3,4]oxadiazol-2-yl]-heptyl}-
 formamide;

15

Benzo[1,3]dioxole-5-carboxylic acid (5-{(R)-1-[(formyl-hydroxy-amino)-methyl]-
 hexyl}-[1,3,4]oxadiazol-1,2-yl)-amide;

N-{(R)-2-[5-(3,5-Dichloro-phenylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy
 formamide;

20

N-[(S)-2-Fluoro-2-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxy

formamide; and

N-{(R)-2-[5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-
 N-hydroxy-formamide.

25

7. A method of treating a bacterial infection by administering to a subject in need
 of treatment a compound according to claim 1.